Ishiguro Hideyuki, Wakasugi Takehiro, Terashita Yukio, Sakamoto Nobuhiro, Tanaka Tatsuya, Sagawa Hiroyuki, Okubo Tomotaka, Takeyama Hiromitsu
Department of Gastroenterological Surgery, Nagoya City University Graduate School of Medical Science, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601 Japan.
Cell Mol Biol Lett. 2016 Jul 28;21:5. doi: 10.1186/s11658-016-0006-0. eCollection 2016.
The prognosis for patients with esophageal cancer remains poor. Therefore, the identification of novel target molecules for the treatment of esophageal cancer is necessary. Here, we investigated the clinicopathological significance of transcription factor 4/transcription factor 7-like 2 (TCF4/TCF7L2) in resectable esophageal squamous cell carcinoma (ESCC), because TCF4/TCF7L2 expression has not been studied in esophageal cancer previously. This study included 79 patients with esophageal cancer who underwent surgery between 1998 and 2005. The expression of the TCF4/TCF7L2 protein in the nucleus of esophageal cancer cells was analyzed using immunohistochemistry. We examined the correlation between TCF4/TCF7L2 expression, clinicopathological factors, and prognosis in patients with ESCC. TCF4/TCF7L2 was expressed in 57 % (45/79) of patients. TCF4/TCF7L2 expression was correlated with T factor (T1 vs. T2-4, = 0.001), stage (I vs. II-IV, =0.0058), Ly factor ( =0.038), and V factor ( =0.038) and did not correlate with age, gender or N factor. Furthermore, patients who were positive for TCF4/TCF7L2 had a significantly lower survival rate than those who were negative for TCF4/TCF7L2 (log-rank test, = 0.0040). TCF4/TCF7L2 expression significantly affected the survival of patients with ESCC. Positive expression of TCF4/TCF7L2 was correlated with a poor prognosis after a curative operation in patients with ESCC.
食管癌患者的预后仍然很差。因此，有必要鉴定用于治疗食管癌的新靶分子。在此，我们研究了转录因子4/转录因子7样2（TCF4/TCF7L2）在可切除食管鳞状细胞癌（ESCC）中的临床病理意义，因为此前尚未在食管癌中研究过TCF4/TCF7L2的表达。本研究纳入了1998年至2005年间接受手术的79例食管癌患者。采用免疫组织化学分析食管癌细胞核中TCF4/TCF7L2蛋白的表达。我们检测了ESCC患者中TCF4/TCF7L2表达、临床病理因素与预后之间的相关性。57%（45/79）的患者表达TCF4/TCF7L2。TCF4/TCF7L2表达与T因子（T1 vs. T2-4，=0.001）、分期（I vs. II-IV，=0.0058）、Ly因子（=0.038）和V因子（=0.038）相关，与年龄、性别或N因子无关。此外，TCF4/TCF7L2阳性患者的生存率显著低于TCF4/TCF7L2阴性患者（对数秩检验，=0.0040）。TCF4/TCF7L2表达显著影响ESCC患者的生存。TCF4/TCF7L2阳性表达与ESCC患者根治性手术后的不良预后相关。
